NasdaqGS:UTHRBiotechs
What United Therapeutics (UTHR)'s Ralinepag Phase 3 Win and $2 Billion Buyback Mean For Shareholders
In early March 2026, United Therapeutics announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary and key secondary endpoints, and the Board authorized a one-year US$2.00 billion share repurchase program including accelerated buybacks.
Together, the robust late-stage data for ralinepag and the large, time-bound buyback highlight how United Therapeutics is pairing pipeline progress with capital returns to...